)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Arrowhead Pharmaceuticals (ARWR) investor relations material
Arrowhead Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary25 Nov, 2025
Executive summary
Achieved first FDA approval for Redemplo, an siRNA therapy for familial chylomicronemia syndrome (FCS), marking transition to commercial stage.
Launched Redemplo with a $60,000 annual price and a unified pricing model across current and future indications.
Entered global licensing and collaboration agreement with Novartis for ARO-SNCA, with $200M upfront and up to $2B in milestones.
Earned $300M in milestone payments from Sarepta Therapeutics related to ARO-DM1 clinical progress.
Signed asset purchase agreement with Sanofi for Visirna Therapeutics, securing $130M upfront and up to $265M in milestones.
Financial highlights
Fiscal 2025 net loss was $1.6M ($0.01/share), a significant improvement from $599M loss ($5/share) in 2024.
Revenue reached $829.4M, driven by licensing and collaboration agreements, mainly Sarepta ($697M) and Sanofi ($130M).
Operating expenses rose to $731M, up $126M year-over-year, due to higher R&D and SG&A costs.
Cash and investments totaled $919.4M as of September 30, 2025, up from $681M a year prior.
Total assets increased to $1.39B from $1.14B year-over-year.
Outlook and guidance
No detailed financial guidance for fiscal 2026; Redemplo sales not expected to materially impact near-term financials.
Cash runway projected to extend into fiscal 2028, even without new deals.
Positioned for multiple new launches and continued pipeline advancement, leveraging the TRIM platform.
Ongoing focus on discovery, clinical development, and business development to drive future growth.
Anticipates multiple late-stage data readouts and potential regulatory submissions in 2026.
REDEMPLO pricing strategy for future indications
Impact of dual-gene RNAi and CNS delivery
Rationale for cash allocation to securities
How will REDEMPLO's SHTG pricing model be justified?
What is the ARO-DIMER-PA CVOT study strategy?
How do recent deals impact future R&D investment?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arrowhead Pharmaceuticals earnings date
Piper Sandler 37th Annual Healthcare Conference3 Dec, 2025
Next Arrowhead Pharmaceuticals earnings date
Piper Sandler 37th Annual Healthcare Conference3 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arrowhead Pharmaceuticals Inc develops therapies that leverage RNA interference (RNAi) to treat genetic diseases. Its pipeline targets conditions in areas such as liver disease, cardiovascular disease, and oncology. The company is headquartered in Pasadena, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage